Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept - Wikidata - wikimedia - TriplyDB

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

http://www.wikidata.org/entity/Q26786766

about

Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration.EGHB010, a Standardized Extract of Paeoniae Radix and Glycyrrhizae Radix, Inhibits VEGF-Induced Tube Formation In Vitro and Retinal Vascular Leakage and Choroidal Neovascularization In Vivo.Aster koraiensis Extract and Chlorogenic Acid Inhibit Retinal Angiogenesis in a Mouse Model of Oxygen-Induced Retinopathy.

P2860

Q33790460-D35CE56F-51B8-45A6-8E08-C968590B6080 Q47758215-50B9C227-BCA9-4A89-AFC4-5040C77F7EE6 Q55018025-6F88DDD0-6529-473F-835C-0BD200F9AE34

P2860

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

http://www.wikidata.org/entity/Q26786766

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@ast

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@en

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@nl

type

label

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@ast

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@en

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@nl

prefLabel

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@ast

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@en

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@nl

P1433

Q26786766-1BDC65E6-C4C2-4E06-856C-91FE598D1082

P1476

Q26786766-E4BAB3DA-F0EB-483B-819A-CBF549B3F35C

P2093

Q26786766-24760185-D50D-4EE7-8F51-B61D38637394

Q26786766-7687F519-1A64-4411-A563-043174B3BC54

Q26786766-9D4A26DF-C960-48BF-BF28-BD981963A4C3

Q26786766-A0A594E2-A558-427F-8592-843BF05A4760

Q26786766-AB7ACA24-85A7-4943-8501-2E3715A6E34E

Q26786766-CF7C8F52-A7E3-4413-BF1C-DC86CFD17900

Q26786766-E12E2373-668B-41D8-BE97-D3F0CE938D7F

P275

Q26786766-B4465D9A-CA8C-4E95-8463-A0F71DBA5E72

P2860

Q26786766-021BE01C-43E5-416E-9E62-FBD1D472EB74

Q26786766-027512DD-669E-4BAD-85DD-1D273E5B919C

Q26786766-0441FD68-0598-4291-A715-C88D7B4AE75D

Q26786766-0B252FA4-901E-4812-B839-01D308443DE8

Q26786766-0B41AE14-A999-4A1E-818C-5BA502447D31

Q26786766-0E33961E-1E24-4E3D-917A-7E072C8CA180

Q26786766-12469C91-50E3-4E84-9F98-4DC5078B3530

Q26786766-12EBE71D-6108-4073-988C-8E0AFF7C71C9

Q26786766-1389CA67-EC62-4BEE-9E9F-B683C873AAD4

Q26786766-143C7635-380A-4EED-9AAC-7253F5A011DD

P2888

Q26786766-46C16B1E-0170-4CCA-AE73-30D98DD82F03

P304

Q26786766-930EF26D-252C-4870-AD78-09268F3B1EAC

P31

Q26786766-5D0BE391-5BAB-4D34-AB5F-0195FC3BCAFC

Q26786766-973218C5-73A5-45F1-8E8D-A8F56CC3AC37

P356

Q26786766-7F620F3A-274D-457E-939E-43C2DBD0EDDE

P407

Q26786766-056E3A42-7F54-467C-9B9B-3CA0ECC8B0BD

P433

Q26786766-674B309D-B43C-4FC9-A327-9122A2C61897

P478

Q26786766-E967C5E8-CAC1-4B4A-92F1-24A56750DA36

P5008

Q26786766-5E168F19-D3F2-4D5A-B3F0-6F68B49F7497

P577

Q26786766-12B2AF3D-9B38-4C8E-9AF1-9AE14200E7CF

Q26786766-F8F009D1-09B9-4B01-9224-7A3903114FDF

P5875

Q26786766-D696006D-4648-4B3C-8833-882B02129892

P6179

Q26786766-FD57D2AF-F187-406A-A486-4A85239186AC

P698

Q26786766-893745E0-78F4-482E-8237-C0A225E7FA1C

P921

Q26786766-174CA38A-7F54-4894-B19D-E03A9E57F521

Q26786766-64A27F95-0D4A-4773-96E8-F0B75DAB4E53

Q26786766-6E2B9BD8-4ECF-4993-A94F-F15A2CD413E9

Q26786766-99EFCD30-97B0-47EC-89BC-4931E5D26D7B

Q26786766-ABC70C73-666D-49FD-B9F3-88E4FAB2A891

Q26786766-D621ECD3-71BD-41E7-A0A1-9D25F3BF9694

P932

Q26786766-35707CAF-62D3-43B9-8257-32C400BF5697

P356

S40266-015-0300-Y

P1433

P1476

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept

@en

P2093

Alfredo García-Layana

http://www.w3.org/2001/XMLSchema#string

Francisco Gómez-Ulla

http://www.w3.org/2001/XMLSchema#string

Javier Araiz

http://www.w3.org/2001/XMLSchema#string

José M Ruiz-Moreno

http://www.w3.org/2001/XMLSchema#string

Luis Arias-Barquet

http://www.w3.org/2001/XMLSchema#string

Marta S Figueroa

http://www.w3.org/2001/XMLSchema#string

Nicholas Reiter

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

Polypoidal Choroidal Vasculopathy in Asians

Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Ranibizumab for neovascular age-related macular degeneration

Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research.

A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interi

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen.

Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).

P2888

s40266-015-0300-y

P304

797-807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40266-015-0300-Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282658994

http://www.w3.org/2001/XMLSchema#string

P6179

1010256240

http://www.w3.org/2001/XMLSchema#string

P698

26442858

http://www.w3.org/2001/XMLSchema#string

P921

Kuhnt-Junius degeneration

cell surface receptor

membrane proteins

recombinant protein

physiological phenomena

P932

4607716

http://www.w3.org/2001/XMLSchema#string